Surrogate Endpoint Failure After Accelerated Approval: Consequences

Introduction

A surrogate endpoint is a laboratory measurement, biological marker, imaging result or other indicator used to predict whether a medicine will provide a meaningful clinical benefit. Examples include reduction in tumour size, viral load or a particular biomarker. It is not necessarily proof that the medicine improves survival, prevents disability or improves a patient's quality of life.

Accelerated approval allows regulators to approve certain medicines for serious diseases on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit. The manufacturer must subsequently conduct confirmatory clinical trials. If those trials fail to establish the expected benefit, serious regulatory, financial, ethical and legal consequences may follow.

Legal and Regulatory Framework

1. United States Food and Drug Administration (FDA): Under Section 506(c) of the Federal Food, Drug, and Cosmetic Act, accelerated approval may be granted on the basis of a surrogate endpoint reasonably likely to predict clinical benefit. The sponsor must conduct post-approval studies to verify that benefit. Failure may result in withdrawal of the relevant approval or indication.

FDA+1

2. Food and Drug Omnibus Reform Act, 2022 (FDORA): Strengthened FDA's authority over confirmatory trials. It permits the agency to require trials to be underway before accelerated approval, demand progress reports and use expedited procedures for withdrawal in appropriate circumstances.

U.S. Food and Drug Administration

3. Indian regulatory framework: India does not have an identical statutory accelerated-approval pathway under the US model. The New Drugs and Clinical Trials Rules, 2019, under the Drugs and Cosmetics Act, 1940, regulate clinical trials, permissions, safety reporting and new-drug approvals. Rule 80 provides for permission to conduct clinical trials, while Rule 81 deals with permission to manufacture or import new drugs for sale or distribution. Regulatory authorities may take action where a product fails applicable safety, efficacy or approval conditions.

Important Case Laws and Regulatory Examples

1. Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609 (1973)

The US Supreme Court examined the statutory requirements for establishing the effectiveness of medicines. It emphasised that drug efficacy must be supported by substantial evidence from adequate and well-controlled investigations. The judgment confirms that regulatory approval must rest on reliable scientific evidence rather than unsupported medical claims. Its principles are relevant when later clinical evidence fails to support an earlier prediction of benefit.

LII / Legal Information Institute

2. Jacob Puliyel v. Union of India (2022)

The Supreme Court of India considered transparency concerning COVID-19 vaccine clinical-trial data. It emphasised the importance of making trial information publicly available in accordance with applicable requirements while protecting participants' privacy. The case is relevant to public accountability when clinical evidence raises questions about a medicine's effectiveness or safety. It did not directly decide accelerated approval or surrogate endpoint failure.

Indian Kanoon

3. Makena (Hydroxyprogesterone Caproate) Withdrawal (FDA, 2023)

This is an important regulatory precedent, although it is not a court judgment. Makena received accelerated approval in 2011 based on an intermediate endpoint considered reasonably likely to predict clinical benefit in preventing preterm birth. Its confirmatory trial failed to establish the expected benefit for mothers and newborns. In April 2023, the FDA withdrew approval after a public hearing.

FDA+1

4. Avastin Breast Cancer Indication Withdrawal (FDA, 2011)

The FDA withdrew the accelerated approval of Avastin for metastatic breast cancer after subsequent studies failed to confirm the expected clinical benefit and identified significant safety concerns. This example demonstrates that an approval may be withdrawn for a particular indication even when the medicine remains approved for other diseases.

JAMA Network+1

Major Legal and Regulatory Consequences

Withdrawal of approval: The regulator may withdraw the drug or the particular approved indication.

Further clinical trials: Sponsors may be required to conduct additional confirmatory studies.

Labelling changes: Warnings, limitations and revised prescribing information may be required.

Financial consequences: Manufacturers may face commercial losses, contractual disputes and possible compensation claims where legally established.

Patient protection: Healthcare professionals and patients must be informed about the failure of expected clinical benefit.

Regulatory liability: Misrepresentation, concealment of trial results or breach of approval conditions may attract legal and regulatory action.

Conclusion

Failure of a surrogate endpoint after accelerated approval creates serious consequences because the initial scientific prediction may not translate into actual patient benefit. The FDA's Makena and Avastin decisions demonstrate how regulators can withdraw an approval or a specific indication when confirmatory evidence is inadequate. In India, the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940 provide the relevant regulatory framework, although India does not have an identical US accelerated-approval system. Ultimately, patient safety, reliable clinical evidence and regulatory accountability must take priority over commercial interests.